<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>67(8)</volume><submitter>Levander S</submitter><funding>Vetenskapsrådet</funding><funding>Cancerfonden</funding><pubmed_abstract>&lt;h4>Objective&lt;/h4>HCV is characterised by its ability to establish chronic infection in hepatocytes and to replicate in the presence of an inflammation. We mimicked this situation in vivo in immune-competent mice by syngeneic transplantation of HCV replicon-containing mouse hepatoma cells.&lt;h4>Design&lt;/h4>A total of 5 million H-2&lt;sup>b&lt;/sup> positive Hep56.1D cells, carrying a subgenomic genotype (gt) 2a replicon (HCV replicon cells) or stably expressing comparable levels of the HCV NS3/4A protease/helicase complex (NS3/4A hepatoma cells), were injected subcutaneously into syngeneic H-2&lt;sup>b&lt;/sup>-restricted mice. Kinetics of tumour growth, HCV RNA replication levels and HCV-specific immune responses were monitored. For immune monitoring, new H-2&lt;sup>b&lt;/sup>-restricted cytotoxic T cell epit</pubmed_abstract><journal>Gut</journal><pagination>1525-1535</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6204962</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.</pubmed_title><pmcid>PMC6204962</pmcid><pubmed_authors>Levander S</pubmed_authors><pubmed_authors>Frelin L</pubmed_authors><pubmed_authors>Long G</pubmed_authors><pubmed_authors>Rupp D</pubmed_authors><pubmed_authors>Ahlen G</pubmed_authors><pubmed_authors>Bartenschlager R</pubmed_authors><pubmed_authors>Sallberg M</pubmed_authors><pubmed_authors>Holmstrom F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.</name><description>&lt;h4>Objective&lt;/h4>HCV is characterised by its ability to establish chronic infection in hepatocytes and to replicate in the presence of an inflammation. We mimicked this situation in vivo in immune-competent mice by syngeneic transplantation of HCV replicon-containing mouse hepatoma cells.&lt;h4>Design&lt;/h4>A total of 5 million H-2&lt;sup>b&lt;/sup> positive Hep56.1D cells, carrying a subgenomic genotype (gt) 2a replicon (HCV replicon cells) or stably expressing comparable levels of the HCV NS3/4A protease/helicase complex (NS3/4A hepatoma cells), were injected subcutaneously into syngeneic H-2&lt;sup>b&lt;/sup>-restricted mice. Kinetics of tumour growth, HCV RNA replication levels and HCV-specific immune responses were monitored. For immune monitoring, new H-2&lt;sup>b&lt;/sup>-restricted cytotoxic T cell epit</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Aug</publication><modification>2026-06-06T22:40:02.444Z</modification><creation>2019-03-27T00:06:06Z</creation></dates><accession>S-EPMC6204962</accession><cross_references><pubmed>28646094</pubmed><doi>10.1136/gutjnl-2016-313579</doi></cross_references></HashMap>